gustavo turecki

Study linking depression to specific altered brain cells opens door to new treatments

keila.depape@mcgill.ca — Tue, 26 Aug 2025 19:24:20 +0000

Researchers at 51�Թ�� and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Promising advance in depression research

amelia.souffrant@mail.mcgill.ca — Tue, 07 Apr 2020 16:20:23 +0000

Depression is a common psychiatric disorder and one of the leading causes of disability worldwide. Antidepressants are the first-line treatment for moderate to severe major depressive episodes. Despite their effectiveness, only 40% of patients respond to the first antidepressant they try. A recent paper in Nature Communication strongly suggests that a particular protein, GPR56, is involved in the biology of depression and the effect of antidepressants.

LA PRESSE | Prévention du suicide: Retrouver le goût à la vie

nathan.menezes@mail.mcgill.ca — Wed, 31 Jan 2018 19:15:13 +0000

Les tentatives de suicide ne sont pas toutes pareilles. Ce n’est pas un phénomène homogène ou unique. "Les gens font des tentatives dans des contextes différents, avec des intentions différentes," précise d’entrée de jeu le psychiatre Gustavo Turecki, qui est aussi directeur du Groupe 51�Թ��d’études sur le suicide et directeur du Réseau québécois sur le suicide, les troubles de l’humeur et troubles associés.

La Presse Plus